Abstract
Background: Metformin’s effects on non-cancer skin diseases are rarely investigated. Objective: The aim of the study was to investigate immune-mediated (urticaria, allergic contact dermatitis, and psoriasis) and androgen-mediated (acanthosis nigricans, hidradenitis suppurativa, and acne) skin diseases associated with metformin use. Methods: Metformin initiators (n = 234,585) and non-metformin initiators (n = 125,921) within the initial 12 months of antidiabetic drug prescription during 1999–2009 were followed up until December 31, 2011. Cox regression weighted for propensity score was used to estimate hazard ratios for metformin initiators versus non-metformin initiators in intention-to-treat (ITT) and per-protocol (PP) analyses. Results: For immune-mediated skin diseases, hazard ratios were 0.930 (95% confidence interval: 0.920–0.940) and 0.930 (0.918–0.943) in ITT and PP analyses, respectively, and the hazard ratios for each specific outcome were all significantly below unity. For androgen-mediated skin diseases, the ITT and PP hazard ratios were 1.110 (1.060–1.162) and 0.990 (0.935–1.048), respectively, and all hazard ratios were not significant for each specific outcome except for acne in the ITT analysis (hazard ratio: 1.116, 95% confidence interval: 1.064–1.170). Conclusion: Metformin use is associated with a significantly lower risk of immune-mediated skin diseases but lacks a preventive effect on androgen-mediated skin diseases.
Journal Section:
Dermato-Endocrinology – Research Article
References
1.
Global Burden of Disease Cancer Collaboration
Fitzmaurice
C
, Abate
D
, Abbasi
N
, Abbastabar
H
, Abd-Allah
F
. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study
. JAMA Oncol
. 2019
;5
(12
):1749
–68
.2.
Giesey
RL
, Mehrmal
S
, Uppal
P
, Delost
ME
, Delost
GR
. Dermatoses of the world: burden of skin disease and associated socioeconomic status in the world
. J Am Acad Dermatol
. 2021
;84
(2
):556
–9
.3.
Boyers
LN
, Karimkhani
C
, Naghavi
M
, Sherwood
D
, Margolis
DJ
, Hay
RJ
. Global mortality from conditions with skin manifestations
. J Am Acad Dermatol
. 2014
;71
(6
):1137
43.e17
.4.
Seth
D
, Cheldize
K
, Brown
D
, Freeman
EF
. Global burden of skin disease: inequities and innovations
. Curr Dermatol Rep
. 2017
;6
(3
):204
–10
.5.
Urban
K
, Chu
S
, Giesey
RL
, Mehrmal
S
, Uppal
P
, Delost
ME
. Burden of skin disease and associated socioeconomic status in Asia: a cross-sectional analysis from the Global Burden of Disease Study 1990–2017
. JAAD Int
. 2021
;2
:40
–50
.6.
Laughter
MR
, Maymone
MBC
, Karimkhani
C
, Rundle
C
, Hu
S
, Wolfe
S
. The burden of skin and subcutaneous diseases in the United States from 1990 to 2017
. JAMA Dermatol
. 2020
;156
(8
):874
–81
.7.
Peng
D
, Sun
J
, Wang
J
, Qi
X
, Li
G
. Burden of skin disease: China, 1990-2019
. China CDC Wkly
. 2021
;3
(22
):472
–5
.8.
Kavita
A
, Thakur
JS
, Narang
T
. The burden of skin diseases in India: global burden of disease study 2017
. Indian J Dermatol Venereol Leprol
. 2021 Oct 30
0
1
5
.9.
Mounessa
J
, Braunberger
T
, Dunnick
CA
, Dellavalle
RP
. Minimal improvements in the global burden of skin disease from 1990 to 2013
. J Am Acad Dermatol
. 2017
;76
(1
):148
9.e2
.10.
He
L
. Metformin and systemic metabolism
. Trends Pharmacol Sci
. 2020
;41
(11
):868
–81
.11.
Nath
M
, Bhattacharjee
K
, Choudhury
Y
. Pleiotropic effects of anti-diabetic drugs: a comprehensive review
. Eur J Pharmacol
. 2020
;884
:173349
.12.
Hirsch
A
, Hahn
D
, Kempná
P
, Hofer
G
, Nuoffer
JM
, Mullis
PE
. Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain
. Endocrinology
. 2012
;153
(9
):4354
–66
.13.
Andræ
F
, Abbott
D
, Stridsklev
S
, Schmedes
AV
, Odsæter
IH
, Vanky
E
. Sustained maternal hyperandrogenism during PCOS pregnancy reduced by metformin in non-obese women carrying a male fetus
. J Clin Endocrinol Metab
. 2020
;105
(12
):3762
–70
.14.
El-Arabey
AA
, Abdalla
M
, Ali Eltayb
W
. Metformin: ongoing journey with superdrug revolution
. Adv Pharm Bull
. 2019
;9
:1
–4
.15.
Tseng
CH
. Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes
. J Am Acad Dermatol
. 2018
;78
(4
):694
–700
.16.
Singh
S
, Bhansali
A
. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)
. BMC Dermatol
. 2016
;16
(1
):12
.17.
Das
A
, Datta
D
, Kassir
M
, Wollina
U
, Galadari
H
, Lotti
T
. Acanthosis nigricans: a review
. J Cosmet Dermatol
. 2020
;19
(8
):1857
–65
.18.
Lee
JK
, Smith
AD
. Metformin as an adjunct therapy for the treatment of moderate to severe acne vulgaris
. Dermatol Online J
. 2017
;23
(11
):13030
.19.
Jennings
L
, Hambly
R
, Hughes
R
, Moriarty
B
, Kirby
B
. Metformin use in hidradenitis suppurativa
. J Dermatolog Treat
. 2020
;31
(3
):261
–3
.20.
Wang
M
, Qu
S
, Ma
J
, Wang
X
, Yang
Y
. Metformin suppresses LPS-induced inflammatory responses in macrophage and ameliorates allergic contact dermatitis in mice via autophagy
. Biol Pharm Bull
. 2020
;43
(1
):129
–37
.21.
Housman
E
, Reynolds
RV
. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations
. J Am Acad Dermatol
. 2014
71
5
847.e1
10
.22.
Tseng
CH
. Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: a retrospective cohort analysis
. Diabetes Metab
. 2017
;43
(5
):438
–45
.23.
Lin
LY
, Warren-Gash
C
, Smeeth
L
, Chen
PC
. Data resource profile: the national health insurance research database (NHIRD)
. Epidemiol Health
. 2018
;40
:e2018062
.24.
Hsieh
CY
, Su
CC
, Shao
SC
, Sung
SF
, Lin
SJ
, Kao Yang
YH
. Taiwan's national health insurance research database: past and future
. Clin Epidemiol
. 2019
;11
:349
–58
.25.
Chang
L
A study of validation on comorbidity derived from claims data. Master thesis
National Yang-Ming University
2004
. (available at: http://140.113.39.130/cgi-bin/gs32/ymgsweb.cgi/ccd=cDjB35/record?r1=1&h1=0). (accessed on 24 December 2022).26.
Tseng
CH
. Metformin is associated with a lower risk of non-Hodgkin lymphoma in patients with type 2 diabetes
. Diabetes Metab
. 2019
;45
(5
):458
–64
.27.
Tseng
CH
. Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: a retrospective cohort analysis of the National Health Insurance database in Taiwan
. Ann Med
. 2015
;47
(7
):561
–9
.28.
Tseng
CH
. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes
. Eur J Clin Invest
. 2016
;46
(1
):70
–9
.29.
Tseng
CH
. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus
. Aging
. 2016
;8
:1636
–49
.30.
Tseng
CH
. Diabetes, insulin use and Helicobacter pylori eradication: a retrospective cohort study
. BMC Gastroenterol
. 2012
;12
:46
.31.
Austin
PC
, Stuart
EA
. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
. Stat Med
. 2015
;34
(28
):3661
–79
.32.
Austin
PC
. The performance of different propensity score methods for estimating marginal hazard ratios
. Stat Med
. 2013
;32
(16
):2837
–49
.33.
Abbas
M
, Moussa
M
, Akel
H
. Type I hypersensitivity reaction
2022 Jul 18
. In: StatPearls [internet]. Treasure island (FL)
StatPearls Publishing
2022 Jan
.34.
Li
Y
, Li
L
. Contact dermatitis: classifications and management
. Clin Rev Allergy Immunol
. 2021
;61
(3
):245
–81
.35.
Kasumagic-Halilovic
E
. Total serum immunoglobulin E levels in patients with psoriasis
. Mater Sociomed
. 2020
;32
(2
):105
–7
.36.
Wang
HC
, Huang
SK
. Metformin inhibits IgE- and aryl hydrocarbon receptor-mediated mast cell activation in vitro and in vivo
. Eur J Immunol
. 2018
;48
(12
):1989
–96
.37.
Caslin
HL
, Taruselli
MT
, Haque
T
, Pondicherry
N
, Baldwin
EA
, Barnstein
BO
. Inhibiting glycolysis and ATP production attenuates IL-33-mediated mast cell function and peritonitis
. Front Immunol
. 2018
;9
:3026
.38.
De Pessemier
B
, Grine
L
, Debaere
M
, Maes
A
, Paetzold
B
, Callewaert
C
. Gut-Skin Axis: current Knowledge of the Interrelationship between microbial dysbiosis and skin conditions
. Microorganisms
. 2021
;9
(2
):353
.39.
Polkowska-Pruszyńska
B
, Gerkowicz
A
, Krasowska
D
. The gut microbiome alterations in allergic and inflammatory skin diseases: an update
. J Eur Acad Dermatol Venereol
. 2020
;34
(3
):455
–64
.40.
Polak
K
, Bergler-Czop
B
, Szczepanek
M
, Wojciechowska
K
, Frątczak
A
, Kiss
N
. Psoriasis and gut microbiome-Current state of art
. Int J Mol Sci
. 2021
;22
(9
):4529
.41.
Toubi
E
, Vadasz
Z
. The emerging role of IL-17 in the immune-pathogenesis of chronic spontaneous urticaria
. Immunotargets Ther
. 2020
;9
:217
–23
.42.
Brar
KK
. A review of contact dermatitis
. Ann Allergy Asthma Immunol
. 2021
;126
(1
):32
–9
.43.
Tseng
CH
. Metformin use is associated with a lower risk of inflammatory bowel disease in patients with type 2 diabetes mellitus
. J Crohns Colitis
. 2021
;15
(1
):64
–73
.44.
Lee
SY
, Lee
SH
, Yang
EJ
, Kim
EK
, Kim
JK
, Shin
DY
. Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17/Treg balance
. PLoS One
. 2015
;10
(9
):e0135858
.45.
Greb
JE
, Goldminz
AM
, Elder
JT
, Lebwohl
MG
, Gladman
DD
, Wu
JJ
Nat Rev Dis Primers
. 2016
;2
:16082
.46.
Crane
ED
, Wong
W
, Zhang
H
, O’Neil
G
, Crane
JD
. AMPK Inhibits mTOR-driven keratinocyte proliferation after skin damage and stress
. J Invest Dermatol
. 2021
;141
(9
):2170
7.e3
.47.
Speirs
C
, Williams
JJL
, Riches
K
, Salt
IP
, Palmer
TM
. Linking energy sensing to suppression of JAK-STAT signalling: a potential route for repurposing AMPK activators
. Pharmacol Res
. 2018
;128
:88
–100
.48.
Liu
Z
, Liao
W
, Zhang
Z
, Sun
R
, Luo
Y
, Chen
Q
. Metformin affects gut microbiota composition and diversity associated with amelioration of dextran sulfate sodium-induced colitis in mice
. Front Pharmacol
. 2021
;12
:640347
.49.
Ceruti
JM
, Leirós
GJ
, Balañá
ME
. Androgens and androgen receptor action in skin and hair follicles
. Mol Cel Endocrinol
. 2018
;465
:122
–33
.50.
Bienenfeld
A
, Azarchi
S
, Lo Sicco
K
, Marchbein
S
, Shapiro
J
, Nagler
AR
. Androgens in women: androgen-mediated skin disease and patient evaluation
. J Am Acad Dermatol
. 2019
;80
(6
):1497
–506
.51.
Riis
PT
, Ring
HC
, Themstrup
L
, Jemec
GB
. The role of androgens and estrogens in hidradenitis suppurativa: a systematic review
. Acta Dermatovenerol Croat
. 2016
;24
(4
):239
–49
.52.
Kesmodel
US
. Information bias in epidemiological studies with a special focus on obstetrics and gynecology
. Acta Obstet Gynecol Scand
. 2018
;97
(4
):417
–23
.53.
Tseng
CH
. Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus
. Eur J Endocrinol
. 2019
;180
(6
):365
–72
.54.
Damiani
G
, Grossi
E
, Berti
E
, Conic
RRZ
, Radhakrishna
U
, Pacifico
A
. Artificial neural networks allow response prediction in squamous cell carcinoma of the scalp treated with radiotherapy
. J Eur Acad Dermatol Venereol
. 2020
;34
(6
):1369
–73
.55.
Damiani
G
, Buja
A
, Grossi
E
, Rivera
M
, De Polo
A
, De Luca
G
. Use of an artificial neural network to identify patient clusters in a large cohort of patients with melanoma by simultaneous analysis of costs and clinical characteristics
. Acta Derm Venereol
. 2020
100
18
adv00323
.56.
Murphree
DH
, Puri
P
, Shamim
H
, Bezalel
SA
, Drage
LA
, Wang
M
. Deep learning for dermatologists: Part I. Fundamental concepts
. J Am Acad Dermatol
. 2022
;87
(6
):1343
–51
.57.
Puri
P
, Comfere
N
, Drage
LA
, Shamim
H
, Bezalel
SA
, Pittelkow
MR
. Deep learning for dermatologists: Part II. Current applications
. J Am Acad Dermatol
. 2022
;87
(6
):1352
–60
.58.
Beltrami
EJ
, Brown
AC
, Salmon
PJM
, Leffell
DJ
, Ko
JM
, Grant-Kels
JM
. Artificial intelligence in the detection of skin cancer
. J Am Acad Dermatol
. 2022
;87
(6
):1336
–42
.59.
Chen
SB
, Novoa
RA
. Artificial intelligence for dermatopathology: current trends and the road ahead
. Semin Diagn Pathol
. 2022
;39
(4
):298
–304
.60.
Hogarty
DT
, Su
JC
, Phan
K
, Attia
M
, Hossny
M
, Nahavandi
S
. Artificial intelligence in dermatology-Where we are and the way to the future: a review
. Am J Clin Dermatol
. 2020
;21
:41
–7
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
